

Medibio Limited (ASX: MEB) ("Medibio" or "the Company") is pleased to report on its activities for the December 2015 quarter.

Highlights

- First revenue of \$20,000 from corporate stress product received during the quarter
- Entered into a Memorandum of Understanding (MOU) with WellNovation Ltd Co - collaboration to introduce Medibio's innovative mental health diagnostics to WellNovation's existing network in Saudi Arabia and the Gulf region
- Entered into a non-binding MOU with Medtronic - a subsidiary of Medtronic plc. (NYSE: MDT) to explore business opportunities and synergies across both companies
- Corporate Wellness Partner Program commenced with mental wellness provider Vital Conversations
- Vital Conversations signed first multinational customer for Medibio's Corporate Stress Test
- Institutional Review Board approval received for Johns Hopkins University School of Medicine allowing study to commence

Corporate

- Rebate of \$1,216,128 received from the Australian Taxation Office under the Research and Development Tax Incentive Program subsequent to the end of the quarter
 - An additional rebate of approximately \$600,000 related to eligible international R&D activities conducted during the 2014/15 financial year also expected to be received this quarter.
-

Corporate Stress Product

Maiden revenue and Memorandum of Understandings signed with WellNovation Ltd Co & Medtronic

During the quarter the Company received first revenue from its corporate stress product. The company also entered into two Memorandum of Understandings (MOUs) with WellNovation Ltd Co (WellNovation) and Medtronic.

WellNovation is a healthcare development company focused on bringing innovative healthcare technologies to Saudi Arabia and the Gulf Cooperation Council (GCC). Under the MOU, Medibio and WellNovation will collaborate to introduce Medibio's innovative mental health diagnostics to WellNovation's existing network in Saudi Arabia and the Gulf region. The initial focus will be on the introduction of Medibio's Corporate Stress product to the state-owned enterprise and military clients of WellNovation.

The MOU also contemplates WellNovation assisting Medibio to achieve regulatory approval for its diagnostic algorithms for depression and other mental health disorders in the Gulf region, with the aim of introducing them as screening tools via its Letter of Intent with the Saudi Ministry of Health.

A second MOU was entered into with Medtronic, a wholly-owned subsidiary of New York Stock Exchange listed Medtronic plc (NYSE: MDT). The non-binding MOU provides a framework under

ASX Market Update



Medibio Limited (ASX: MEB)

which Medibio and Medtronic will enter discussions around a proposed strategic agreement covering business opportunities and synergies across both companies.

Corporate Wellness Program Commenced with Wellness Partner Vital Conversations

The Company commenced its Corporate Wellness Partner Program during the quarter.

In November, Medibio announced that its first Corporate Wellness Partner, Vital Conversations, had reached agreement with its first customer for Medibio's Corporate Stress test. Vital Conversations is a mental wellness provider in Western Australia that provides proactive psychological health services to some of the largest corporations in Western Australia as well as the public and not-for-profit sectors.

The customer corporation is a leading international professional services company with more than 5,000 employees in Australia and 200,000 worldwide.

The agreement covers a commercial pilot program involving the corporation's Western Australian staff with roll out, conditional upon the results of the pilot, to begin in Western Australia. Pre-registrations for the pilot program in November doubled the planned 50-person pilot program and closed early at 100 participants. The pilot remains on track to begin in February.

Under the agreement with Vital, Medibio will provide data analytics and reporting on a per test basis to Vital Conversations, its customer, and their employees. Revenue net to Medibio is in line with prior guidance of between \$40-60 per staff member per test.

IRB approval received for Johns Hopkins University School of Medicine study

The Company's study with The Johns Hopkins University School of Medicine (JHM) is underway after it received approval from the JHM Institutional Review Board during the quarter.

The study is intended to clinically validate the use of MEB's Circadian Heart Rate (CHR) technology to differentiate between depressed and non-depressed individuals, and provide clinical data to support FDA certification of the Company's proprietary software algorithm for use as an objective method to differentiate between depressed and non-depressed individuals. The study will comprise approximately 100 subjects, split between participants with Major Depressive Disorder (MDD) and participants without a mental health disorder.

The study will be carried out at The Johns Hopkins University School of Medicine, headquartered in Baltimore, Maryland. JHM is a \$7 billion integrated global health enterprise and one of the leading health care systems in the United States with over 124 years of commitment to community care with ground-breaking research, teaching, and medical services to patients worldwide.

ASX Market Update



Medibio Limited (ASX: MEB)

Corporate

R&D Tax Incentive Refund

Subsequent to the end of the quarter Medibio received \$1,216,128 from the Australian Taxation Office under the Research and Development Tax Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the 2014/15 financial year.

The Company anticipates that it will receive an additional rebate of approximately \$600,000 related to eligible international R&D activities conducted during the 2014/15 financial year in the current quarter.

Annual General Meeting

The Company's Annual General Meeting was held on Monday 30 November 2015. All resolutions put to the meeting were passed unanimously on a show of hands.

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress, and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in a clinical diagnosis. Studies are currently being undertaken by Johns Hopkins University School of Medicine and Ottawa University, among others, to validate the clinical utility of the test. This will potentially enable Medibio's technology to be the first FDA approved, objective, evidence based approach to the diagnosis mental health disorders for the medical industry. The technology also provides an objective method for the assessment of stress and mental wellbeing which can be translated to the workplace stress/wellbeing market, wearable technology, and App market. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.

Further Information:	
Medibio Shareholder Enquiries:	Medibio Investor Relations:
Kris Knauer Executive Director: Medibio Limited kris.knauer@Medibio.com.au T: +61 (0)411 885 979	Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

Medibio Limited

ABN

58 008 130 336

Quarter ended ("current quarter")

31 December 2015

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (...6... months) \$A'000
1.1	Receipts from customers	20	20
1.2	Payments for (a) staff costs	(162)	(252)
	(b) advertising and marketing	-	-
	(c) research and development	(406)	(689)
	(d) leased assets	-	-
	(e) other working capital	(456)	(897)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	8	10
1.5	Interest and other costs of finance paid	(137)	(193)
1.6	Income taxes paid	-	-
1.7	Other (GST refunds)	-	98
Net operating cash flows		(1,133)	(1,903)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'ooo	Year to date (..6..... months) \$A'ooo
1.8 Net operating cash flows (carried forward)	(1,133)	(1,903)
Cash flows related to investing activities		
1.9 Payment for acquisition of:	-	-
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other	-	-
	-	-
Net investing cash flows		
1.14 Total operating and investing cash flows	(1,133)	(1,903)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	-	3,092
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other (less Equity raising costs)	-	(244)
	-	2,848
Net financing cash flows		
Net increase (decrease) in cash held	(1,133)	945
1.21 Cash at beginning of quarter/year to date	3,026	948
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	1,893	1,893

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	114
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions Directors fees for the quarter	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Financing facilities available

Add notes as necessary for an understanding of the position.

	Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-
3.2	Credit standby arrangements	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	54	244
4.2	Deposits at call	1,839	2,782
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		1,893	3,026


Note – The R&D Tax refund of \$1,216,128 for the 30 June 2015 Tax period was received 12 January 2016 and is not reflected in this report

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	
5.2	Place of incorporation or registration	
5.3	Consideration for acquisition or disposal	
5.4	Total net assets	
5.5	Nature of business	

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here: Date: 31 January 2016
 (Company secretary)

+ See chapter 19 for defined terms.

Print name: Robert Lees

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.